CN Patent

CN121175053A — 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防

Assigned to Boehringer Ingelheim Vetmedica GmbH · Expires 2025-12-19 · 0y expired

What this patent protects

本发明涉及一或多种SGLT‑2抑制剂或其药学上可接受的形式以及替米沙坦或其药学上可接受的形式的组合的用途，尤其是用于预防和/或治疗非人类哺乳动物/非人类哺乳动物患者、诸如犬或猫中的一或多种肾脏疾病和/或高血压的用途。

USPTO Abstract

本发明涉及一或多种SGLT‑2抑制剂或其药学上可接受的形式以及替米沙坦或其药学上可接受的形式的组合的用途，尤其是用于预防和/或治疗非人类哺乳动物/非人类哺乳动物患者、诸如犬或猫中的一或多种肾脏疾病和/或高血压的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN121175053A
Jurisdiction
CN
Classification
—
Expires
2025-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Vetmedica GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.